{"id":42603,"date":"2023-04-30T17:49:47","date_gmt":"2023-04-30T21:49:47","guid":{"rendered":"https:\/\/www.sisinternational.com\/?page_id=42603"},"modified":"2026-05-05T17:01:22","modified_gmt":"2026-05-05T21:01:22","slug":"marktforschung-fur-klinische-diagnostik","status":"publish","type":"page","link":"https:\/\/www.sisinternational.com\/de\/losungen\/marktforschung-im-gesundheitswesen-2\/marktforschung-fur-klinische-diagnostik\/","title":{"rendered":"Clinical Diagnostics Market Research | SIS International"},"content":{"rendered":"
\n

Marktforschung f\u00fcr klinische Diagnostik<\/a><\/h1>\n
\"SIS<\/figure>\n<\/p>\n

Clinical Diagnostics identifies the presence or absence of a disease or medical condition. Medical professionals do Clinical Diagnostics through various tests and procedures. The diagnostic process involves a series of steps. For example, the process may include medical history, physical examination, and laboratory tests. They may also consist of imaging studies and other diagnostic<\/a> procedures. Medical professionals use all these methods to make a definitive diagnosis. Or, they may use them to rule out potential conditions.<\/p>\n

Eine weitere Funktion der klinischen Diagnostik ist die Erkennung und Behandlung verschiedener Gesundheitszust\u00e4nde. Sie erkennen h\u00e4ufige Beschwerden (zum Beispiel Grippe). Sie erkennen auch komplexere und chronische Krankheiten wie Krebs und Diabetes. Dar\u00fcber hinaus h\u00e4ngt viel von den Test- und Verfahrensentwicklern ab. Sie haben sichergestellt, dass sie genaue und zuverl\u00e4ssige Ergebnisse liefern k\u00f6nnen. Diese Ergebnisse sollten Behandlungsentscheidungen leiten und die Ergebnisse der Patienten verbessern.<\/p>\n

Einige Beispiele f\u00fcr klinische Diagnosetests und -verfahren sind Blut- und Urintests. Bildgebungsstudien wie R\u00f6ntgen- und MRT-Scans sind ebenfalls diagnostisch. Dasselbe gilt f\u00fcr Biopsien und genetische Tests. Ein weiterer wichtiger Punkt ist, dass die spezifischen Tests und Verfahren von der vermuteten Erkrankung abh\u00e4ngen. Sie beziehen sich auch auf die Symptome und die Krankengeschichte des Patienten.<\/p>\n

Warum ist klinische Diagnostik wichtig?<\/h2>\n

Klinische Diagnostik ist aus mehreren Gr\u00fcnden unerl\u00e4sslich, unter anderem f\u00fcr die Fr\u00fcherkennung und Pr\u00e4vention. Tats\u00e4chlich erm\u00f6glicht die klinische Diagnostik die Fr\u00fcherkennung von Krankheiten und Beschwerden. Eine Fr\u00fcherkennung kann dazu beitragen, die weitere Entwicklung schwerwiegenderer Komplikationen zu verhindern. Dar\u00fcber hinaus sind eine fr\u00fchzeitige Diagnose und Behandlung bei Krebs, Herz-Kreislauf-Erkrankungen und Diabetes von entscheidender Bedeutung. Sie kann die Ergebnisse verbessern und die Sterblichkeitsrate senken.<\/p>\n

Klinische Diagnostik liefert genaue und zuverl\u00e4ssige Informationen \u00fcber den Zustand eines Patienten. Diese Informationen sind f\u00fcr fundierte Behandlungsentscheidungen unerl\u00e4sslich. Ganz zu schweigen davon, dass Patienten ohne eine richtige Diagnose m\u00f6glicherweise eine unzureichende und unangemessene Behandlung erhalten. Schlimmer noch, die Behandlung kann sch\u00e4dlich oder lebensbedrohlich sein.<\/p>\n

Mithilfe klinischer Diagnostik l\u00e4sst sich die Reaktion eines Patienten auf eine Behandlung im Laufe der Zeit \u00fcberwachen. Anhand dieser Informationen k\u00f6nnen Gesundheitsdienstleister Behandlungspl\u00e4ne anpassen. Au\u00dferdem k\u00f6nnen sie so sicherstellen, dass die Patienten die bestm\u00f6gliche Versorgung erhalten.<\/p>\n

Die klinische Diagnostik spielt in der medizinischen Forschung und Entwicklung eine entscheidende Rolle. Mediziner nutzen sie, um neue Therapien und Medikamente zu testen. Sie k\u00f6nnen auch neue Biomarker und Ziele f\u00fcr die Behandlung von Krankheiten identifizieren.<\/p>\n

Um es klarzustellen: Klinische Diagnostik ist f\u00fcr die Verbesserung der Patientenergebnisse und den Fortschritt des medizinischen Wissens von entscheidender Bedeutung. Sie erm\u00f6glicht die genaue Diagnose verschiedener Krankheiten und Beschwerden. Sie erm\u00f6glicht auch eine wirksame Behandlung, was zu besseren Gesundheitsergebnissen f\u00fcr die Patienten f\u00fchrt.<\/p>\n<\/div>\n

Clinical Diagnostics Marktforschung<\/a>: How Leaders Build Defensible Launch Strategy<\/h1>\n

Clinical diagnostics market research now decides which assays reach reimbursement and which stall in pilot accounts. The diagnostics buyer is no longer a single pathologist. It is a procurement committee balancing reagent cost, instrument footprint, LIS integration, and payer coverage decisions. Winning teams treat that complexity as an addressable variable, not a barrier.<\/p>\n

The opportunity is significant. Molecular diagnostics, companion diagnostics (CDx), point-of-care (POC) platforms, and laboratory-developed tests (LDTs) are converging into a single competitive arena. The firms gaining share are the ones running disciplined primary research against the actual decision unit: lab directors, KOL pathologists, payer medical directors, and health system supply chain leads.<\/p>\n

What Sophisticated Clinical Diagnostics Market Research Now Measures<\/h2>\n

The conventional approach maps physician preference and stops there. The better approach maps the full reimbursement-to-utilization chain. That means quantifying CPT code coverage decisions, PAMA-driven price compression on the Clinical Laboratory Fee Schedule, and the gating effect of MolDX local coverage determinations on assay adoption.<\/p>\n

Three measurement layers separate strong diagnostics research from generic physician surveys. First, payer value story testing against medical policy criteria. Second, lab director willingness-to-validate scoring, which predicts adoption faster than physician intent. Third, KOL mapping that distinguishes guideline authors from prescribing volume leaders. The two rarely overlap.<\/p>\n

SIS International’s structured expert interviews with pathologists, oncologists, and reproductive health specialists in tier-one and tier-two Indian metros surfaced a pattern most secondary reports miss: in molecular diagnostics, ordering behavior follows turnaround time and send-out logistics more than analytical sensitivity, once a minimum performance bar is met.<\/span> That insight reframes commercial priorities for any oncology or NIPT entrant.<\/p>\n

Why Companion Diagnostics Demand a Different Research Design<\/h2>\n

Companion diagnostics sit inside a pharma launch. The research question is not “will physicians order this test.” It is “will the test keep pace with therapy uptake across reference labs, hospital labs, and decentralized POC settings.” Roche, Illumina, and Thermo Fisher build CDx commercial strategy on parallel-track studies that interview pharma alliance managers and lab medical directors in the same wave.<\/p>\n

Real-world evidence (RWE) generation runs alongside. Payers increasingly demand outcomes data tied to test-directed therapy before issuing positive coverage. Research design that ignores this produces a value story the medical policy team will reject in the first review cycle.<\/p>\n

Point-of-Care and Decentralized Testing: A Distinct Decision Unit<\/h2>\n

POC molecular platforms from Cepheid, BioFire, and Abbott shifted procurement authority away from central lab directors toward emergency department leadership, urgent care operators, and retail clinic chains. Each buyer applies different criteria. ED leaders weigh door-to-disposition time. Retail operators weigh CLIA-waived status and cartridge cost per test. Central labs weigh menu breadth and middleware integration.<\/p>\n

Research that treats POC as one segment loses precision. The leading sponsors run segmented quantitative work with separate sample frames per care setting, then triangulate against installed base analytics from GPO contract data.<\/p>\n

Geographic Nuance Drives Forecast Accuracy<\/h2>\n

Diagnostics adoption curves diverge sharply across markets. India’s molecular diagnostics market grows through standalone reference labs and oncology-focused chains. Brazil’s growth concentrates in private hospital networks and SUS tender cycles. Germany’s path runs through statutory health insurance EBM coding decisions. China’s NMPA pathway and volume-based procurement rewrite unit economics on entry.<\/p>\n

Across SIS International Research engagements in Brazilian healthcare, mixed-methodology designs combining hospital procurement interviews with quantitative physician surveys have consistently produced forecast variance under fifteen percent against actual two-year uptake, where single-method secondary forecasts have drifted further.<\/span> The discipline is straightforward: pair installed base reality with stated intent, then weight by reimbursement gating.<\/p>\n

The SIS Diagnostics Decision-Unit Framework<\/h2>\n

For pillar planning, the framework below organizes primary research scope across the four buyers that determine commercial outcome.<\/p>\n

\n\n\n\n\n\n\n\n\n
Decision Unit<\/th>\nPrimary Lever<\/th>\nUntersuchungsmethode<\/th>\n<\/tr>\n<\/thead>\n
Lab Director \/ Pathologist<\/td>\nValidation burden, menu fit<\/td>\nB2B expert interviews, willingness-to-validate scoring<\/td>\n<\/tr>\n
Ordering Physician (KOL + community)<\/td>\nClinical utility, guideline alignment<\/td>\nQuantitative survey, conjoint on test attributes<\/td>\n<\/tr>\n
Payer Medical Director<\/td>\nEvidence package, coverage policy<\/td>\nPayer value story testing, RWE gap analysis<\/td>\n<\/tr>\n
Health System Procurement \/ GPO<\/td>\nTotal cost, contract structure<\/td>\nProcurement interviews, TCO modeling<\/td>\n<\/tr>\n<\/tbody>\n<\/table>\n<\/figure>\n

Source: SIS International Research<\/em><\/p>\n

What Separates Launch-Ready Research From Reference-Shelf Research<\/h2>\n

Three signals indicate research that will hold up in a launch readiness review. The sample frame names specific institution types and regions, not “US hospitals.” The instrument tests price points anchored to actual CPT reimbursement, not arbitrary willingness-to-pay scales. The output ties directly to medical affairs, market access, and commercial workstreams with named decisions assigned to each.<\/p>\n

SIS International’s proprietary research in clinical mobility and diagnostics adoption across US and UK hospital systems found that IT integration friction, specifically LIS and EMR middleware compatibility, was the single largest predictor of replacement-cycle losses for incumbent platforms.<\/span> Sponsors who quantified that variable in advance won net-new accounts at materially higher rates.<\/p>\n

Where the Market Is Moving<\/h2>\n

Liquid biopsy, multi-cancer early detection (MCED), AI-enabled digital pathology, and next-generation sequencing menu expansion are reshaping competitive boundaries. Guardant Health, Exact Sciences, GRAIL, and Natera each compete on a different combination of clinical evidence depth, payer coverage breadth, and channel access. Research that benchmarks them on a single axis will mislead the strategy team.<\/p>\n

The forward question for diagnostics leaders is not market size. It is which decision-unit configurations in which geographies will convert evidence into reimbursed volume fastest. Clinical diagnostics market research, designed around that question, becomes a launch asset rather than a deck.<\/p>\n

Key Questions<\/h2>\n
\"SIS<\/figure>\n

Senior diagnostics leaders engaging SIS most often ask how to size molecular diagnostics opportunity in emerging markets, how to structure payer evidence for a CDx launch, and how to segment POC buyers by care setting. Each requires a different primary research design and a different sample frame.<\/p>\n

\u00dcber SIS International<\/h2>\n

SIS International<\/a> bietet quantitative, qualitative und strategische Forschung an. Wir liefern Daten, Tools, Strategien, Berichte und Erkenntnisse zur Entscheidungsfindung. Wir f\u00fchren auch Interviews, Umfragen, Fokusgruppen und andere Methoden und Ans\u00e4tze der Marktforschung durch. Kontakt<\/a> f\u00fcr Ihr n\u00e4chstes Marktforschungsprojekt.<\/p>\n

\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n\n<\/p>\n

\n

Related SIS Resources<\/h3>\n